Core Viewpoint - The academic exchange conference focused on the integration of technology and nutrition management, aiming to enhance public health through innovative solutions and collaborative efforts among various stakeholders [1][3][19]. Group 1: Policy and Technological Empowerment - The conference highlighted the foundational role of nutrition in improving national health and quality of life, with emphasis on the need for government, enterprises, and society to work together in implementing the National Nutrition Plan [6][15]. - The "Healthy China 2030" initiative sets clear and quantifiable goals, aligning with the strategic direction of companies like Nu Skin, which focuses on leveraging advanced technologies such as gene expression science and artificial intelligence in health management [5][19]. Group 2: Clinical and Practical Insights - Experts discussed the importance of clinical nutrition interventions and the need for innovative approaches in health management, particularly in the context of chronic disease prevention [10][12]. - The concept of "hidden hunger" was introduced, emphasizing the need for balanced diets and healthy lifestyles to mitigate chronic disease risks [8][12]. Group 3: Technological Innovations - Nu Skin introduced the PRYSM iO hyperspectral scanner, a non-invasive device that measures skin carotenoid levels to assess antioxidant capacity and nutritional status, representing a shift towards scientific quantification in health management [12][13]. - The device's development is based on over 40 years of research and aims to provide a portable tool for community and family health management [12][19]. Group 4: Collaborative Efforts and Future Directions - The conference underscored the need for collaboration among various sectors, including media, healthcare, and enterprises, to promote proactive health management and enhance public understanding of nutrition [15][16]. - Future initiatives will focus on expanding insurance coverage for nutritional services and improving access to quality healthcare resources in communities [15][16].

Core Insights - The academic exchange conference focused on innovative technologies in precision nutrition, chronic disease prevention, and the value of clinical nutrition interventions, aiming to create a collaborative innovation platform for nutrition health management and industry upgrades [1][3]. Group 1: Industry Trends - The "Healthy China 2030" initiative sets clear and quantifiable goals, positioning China at the forefront of global health strategies, with companies like Nu Skin aligning their strategic direction with this national plan [3]. - The conference highlighted the need for collaboration among government, enterprises, and society to implement the National Nutrition Plan, emphasizing the importance of innovation in producing high-quality health foods [3]. Group 2: Technological Innovations - Nu Skin introduced the PRYSM iO hyperspectral scanner, which allows for non-invasive measurement of skin carotenoid levels, reflecting antioxidant capacity and nutritional status, thus transitioning nutritional health management from vague assessments to scientific quantification [5][6]. - The scanner utilizes Raman spectroscopy principles and AI-driven machine learning to generate a body defense index based on skin carotenoid levels, addressing the gap between health expectancy and actual lifespan [5][6]. Group 3: Clinical Perspectives - Clinical nutrition should follow a "5-step therapy" approach, focusing on tailored nutritional education and supplementation for specific populations such as cancer patients, the elderly, and pregnant women [4][5]. - Experts emphasized the importance of balanced diets and healthy lifestyles in reducing chronic disease risks, advocating for adherence to the 2022 Dietary Guidelines for Chinese Residents [4].

Core Insights - The meeting between Shanghai's Commerce Commission Director Zhu Min and Nu Skin Enterprises CEO Ritch N. Wood highlighted the ongoing development of Shanghai as an international consumption center, emphasizing the city's vast consumer market and growth opportunities for both domestic and international brands [1][3]. Group 1: Shanghai's Consumer Market - Shanghai's consumer market is expanding, driven by initiatives like "First Launch Shanghai" which supports the debut of brands and stimulates new consumption dynamics [3]. - The beauty and health industries in Shanghai are experiencing rapid growth, with continuous market size expansion and emerging growth points such as online sales and senior consumer segments [3]. - Future increases in residents' income and heightened health awareness among consumers are expected to further drive industry upgrades [3]. Group 2: Nu Skin Enterprises' Commitment - Nu Skin has been operating in Shanghai for 25 years, establishing its Greater China headquarters and R&D center in the city, which is viewed as a global strategic hub due to its favorable business environment and concentration of innovation and talent [3]. - The company expressed its intention to increase investments in Shanghai, actively participate in consumption promotion activities, and launch new products tailored to the local market [3]. - Nu Skin aims to contribute significantly to the construction of Shanghai as an international consumption center by leveraging new opportunities arising from industry upgrades [3].

Core Insights - Stonegate Capital Partners has initiated coverage on Nu Skin Enterprises Inc. (NUS) [1] - NUS reported revenue of $386.1 million, adjusted net income of $21.1 million, and adjusted EPS of $0.43, exceeding guidance [1] - The Rhyz Manufacturing segment experienced a 17% year-over-year revenue growth [1] - Gross margin for the quarter was 68.8%, reflecting a quarter-over-quarter expansion of 106 basis points from Q1 2025 [1] - Adjusted net income grew by 103.5% year-over-year, driven by revenue growth and operational optimization [1] - The company is positioned for a solid second quarter of 2025 with continued net income margin expansion [1] Financial Performance - Revenue was at the high end of the guidance range, which was between $355.0 million and $390.0 million [1] - Adjusted EPS of $0.43 significantly outpaced the guidance range of $0.20 to $0.30 [1] - Latin America revenue increased by 107% year-over-year [7] - The company achieved a net cash position ahead of schedule [7] Strategic Developments - The expansion in India and the launch of the Prysm iO device are on track [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Exact name of registrant as specified in its charter) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____________ TO _____________ Commission File Number: 001-12421 NU SKIN ENTERPRISES, INC. (State or other jurisdicti ...

Financial Data and Key Metrics Changes - The company reported revenue of $386.1 million for Q2 2025, achieving the high end of its guidance range and significantly exceeding the earnings per share forecast with $0.43, well above the guidance range of $0.20 to $0.30 [6][18] - Gross margin for Q2 was 68.8%, down from 70% in the prior year, while the core Nu Skin business gross margin improved to 77.5%, up 140 basis points year over year [18][19] - Operating margin improved to 8%, up from an adjusted operating margin of 5.4% in the prior year, reflecting operational efficiency efforts [20] Business Line Data and Key Metrics Changes - The Rise segments performed well, with manufacturing reporting a 17% year-over-year increase [7][14] - Latin America showed strong year-over-year growth, exceeding 100% in revenue, customers, and sales leaders, while North America faced declines due to macro pressures [6][12] - Japan reported growth, benefiting from a strong subscription-based wellness business, while South Korea and China experienced revenue declines due to economic challenges [7][12] Market Data and Key Metrics Changes - Latin America continues to outperform expectations, while North America, China, and Korea are under scrutiny for potential impacts on guidance [26][27] - Europe and Africa showed improving trends in customer engagement, and the Pacific region experienced growth, although Southeast Asia remained sluggish [7][12] Company Strategy and Development Direction - The company is focused on launching its innovative wellness platform, Prism IO, which will provide personalized health insights and product recommendations [8][10] - The developing market strategy is crucial, with significant progress in Latin America and plans for a premarket opening in India by Q4 2025 [12][13] - Project Accelerate aims to improve operational efficiencies and expand margins, with a target gross margin of 78% for the core business [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and highlighted the importance of disciplined cost management [20][22] - The company anticipates revenue for Q3 2025 to be between $360 million and $390 million, with full-year revenue projected at $1.48 billion to $1.55 billion [22][23] - Management remains focused on driving operational performance and maintaining a strong financial position despite ongoing global challenges [23] Other Important Information - The company achieved a net cash positive position for the first time in over four years, ending the quarter with $264 million in cash [21] - A dividend of approximately $3 million was returned to shareholders, with $157.4 million remaining under the current share repurchase authorization [21] Q&A Session Summary Question: Thoughts on guidance and potential impacts from initiatives or geographies - Management noted that Latin America is overperforming, while North America is facing challenges, particularly in Korea and China due to macro uncertainties [26][27] Question: Insights on Latin America's performance and future potential - Management highlighted a simplified operational model and a three-pronged strategy focusing on product, business model, and operational efficiency as key to success in Latin America [30][31] Question: Future margin improvement opportunities - Management indicated ongoing efforts in inventory management and selling expense optimization, with confidence in continued margin improvements [34][35] Question: Capital allocation priorities for the second half of the year - Management emphasized investing in growth opportunities, particularly in Prism IO and developing markets like India, while also servicing debt and maintaining dividends [36][39]

Financial Performance - Q2 2025 revenue was $386.1 million, a decrease of 12.1% year-over-year[6] - Q2 2025 EPS was $0.43, compared to $(2.38) in Q2 2024, or $0.21 excluding impairment and other charges[6] - The company forecasts Q3 2025 revenue to be between $360 million and $390 million, a decrease of 16% to 9% year-over-year[27] - The company projects 2025 revenue to be between $1.48 billion and $1.55 billion, a decrease of 15% to 11% year-over-year[27] - The company anticipates 2025 EPS to be between $3.05 and $3.25, or $1.15 to $1.35 excluding the Mavely gain and other charges[27] Regional Performance - Mainland China accounted for 14% of Q1 revenue distribution[6] - Americas accounted for 7% of Q1 revenue distribution[6] - Revenue from Mainland China decreased by 18% to $53.2 million[10] - Revenue from Americas decreased by 14% to $72.9 million[10] Customer and Affiliate Metrics - Total customers decreased by 14% year-over-year[6] - Total paid affiliates decreased by 16% year-over-year[6] - Total sales leaders decreased by 23% year-over-year[6]

Exhibit 99.1 FOR IMMEDIATE RELEASE Nu Skin Enterprises Reports Second Quarter Revenue at High End of Guidance and Earnings Per Share Above Guidance Company generates strong operating margin and cash position; narrows revenue and raises EPS guidance Q3 and Full-year 2025 Outlook | Q3 2025 Revenue | $360 to $390 million; (16)% to (9)% or (13)% to (5)% excluding Mavely 2024 revenue | | --- | --- | | | • Approximately (1)% FX impact | | Q3 2025 EPS | $0.25 to $0.35 | | 2025 Revenue | $1.48 to $1.55 billion; (15 ...

Q1 2025 Overview Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited ...

Revenue Performance - Revenue for Q1 2025 decreased by 12.7% to $364.5 million, down from $417.3 million in Q1 2024, with a 3.0% negative impact from foreign-currency fluctuations[74] - Total revenue for Q1 2025 decreased by 12.7% to $364.5 million, down from $417.3 million in Q1 2024[102] - Revenue from the Americas segment decreased by 8.0% to $69.1 million, while the Mainland China segment saw a decline of 21.8% to $47.8 million[79] - The total revenue decline of 12.7% was attributed to macroeconomic challenges affecting consumer spending and customer acquisition[75] Customer Metrics - The number of Customers, Paid Affiliates, and Sales Leaders declined by 11%, 15%, and 20% year-over-year, respectively[74] - Total customers decreased by 11% year-over-year to 776,712, with significant declines in Mainland China (25%) and South Korea (28%) markets[84] - Paid affiliates decreased by 15% year-over-year to 131,518, with the largest drop in Southeast Asia/Pacific (25%) and South Korea (20%) markets[84] - Sales leaders decreased by 20% year-over-year to 31,036, with a notable decline in Mainland China (35%) and Southeast Asia/Pacific (18%) markets[84] Earnings and Profitability - Earnings per share for Q1 2025 increased to $2.14, compared to $(0.01) in the prior-year period, primarily due to a pre-tax gain of approximately $176.2 million from the sale of the Mavely business[76] - Net income for Q1 2025 was $107.5 million, a significant increase from a net loss of $(0.5) million in Q1 2024[113] - Gross profit margin decreased to 67.8% in Q1 2025 from 70.5% in Q1 2024, impacted by lower margins in owned manufacturing entities[103] - Selling expenses as a percentage of revenue decreased to 32.5% in Q1 2025 from 36.8% in Q1 2024, reflecting cost-saving measures[105] - General and administrative expenses decreased to $113.2 million in Q1 2025 from $124.6 million in Q1 2024, primarily due to reduced labor and promotional expenses[106] Capital and Cash Management - As of March 31, 2025, working capital increased to $264.6 million from $242.0 million as of December 31, 2024, primarily due to proceeds from the sale of Mavely[115] - The company had $213.6 million in cash and cash equivalents as of March 31, 2025, up from $198.0 million at the end of 2024[121] - The company repurchased 0.6 million shares of Class A common stock for $5.0 million in Q1 2025, with $157.4 million remaining available for repurchases[119] - The company maintains a consolidated leverage ratio not exceeding 2.75 to 1.00 and was in compliance with all debt covenants as of March 31, 2025[117] Future Outlook and Strategic Initiatives - The company anticipates nominal revenue from its India market pre-opening in Q4 2025, with a formal launch planned for mid-2026[75] - The company is focusing on business model optimization and the rollout of enhancements to its sales performance plan in 2025[75] - The company is preparing for the launch of its next connected device, the Prysm iO, as part of its long-term vision[75] Tax and Financial Gains - The effective tax rate for Q1 2025 was 20.1%, benefiting from the Mavely sale, compared to 148.4% in the prior-year period[112] - The company recorded a pre-tax gain of $176.2 million from the sale of the Mavely entity for $230 million in January 2025[110] Cash Flow and Dividends - In Q1 2025, the company generated $0.4 million in cash from operations, a decrease from $3.3 million in the same period last year[114] - A quarterly cash dividend of $0.06 per share was declared in February 2025, totaling $3.0 million paid on March 5, 2025[120] Currency and Repatriation - The company has $30.9 million in cash denominated in Chinese RMB, with restrictions on repatriation until necessary financial statements are filed[122] - The company plans to repatriate undistributed earnings from non-U.S. operations as necessary, considering cash needs for dividends, stock repurchases, and capital investments[122]